Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
The Akt activation inhibitor triciribine and the farnesyltransferase inhibitor tipifarnib have modest to little activity in clinical trials when used as single agents. In this article, preclinical data show that the combination is more effective than single agents both in cultured cells and in vivo....
Những tác giả chính: | Balasis, M, Forinash, K, Chen, Y, Fulp, W, Coppola, D, Hamilton, A, Cheng, J, Sebti, S |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
2011
|
Những quyển sách tương tự
-
Chromatin Modifications Sequentially Enhance ErbB2 Expression in ErbB2-Positive Breast Cancers
Bằng: Sathish Kumar Mungamuri, et al.
Được phát hành: (2013-10-01) -
Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition
Bằng: Flores Juana M, et al.
Được phát hành: (2010-07-01) -
Proteolytic processing of ErbB4 in breast cancer.
Bằng: Maija Hollmén, et al.
Được phát hành: (2012-01-01) -
Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK.
Bằng: Yong-Liang Yao, et al.
Được phát hành: (2013-01-01) -
Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
Bằng: Sho Ueno, et al.
Được phát hành: (2020-06-01)